PoreWise One finding · Human trial · 2015
Study title
Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial
- Kind of evidence
- Human trial 2015 · 962 people · adults with moderate-to-severe papulopustular rosacea · PMID 25228137
- Measured outcome
- Skin effect
- Year
- 2015
- Who was studied
- 962 adults with moderate-to-severe papulopustular rosacea
- Sample size
- 962
- Measured outcome
- In moderate-to-severe papulopustular rosacea, once-daily ivermectin 1% cream reduced inflammatory lesion counts by 83.0% from baseline at 16 weeks versus 73.7% for twice-daily metronidazole 0.75% cream (P<0.001, 962 participants), and more subjects reached 'clear' or 'almost clear' on the investigator's global assessment (84.9% vs 75.4%, P<0.001).
- Certainty
- High
- Who was measured
- Prescription topical treatment for papulopustular rosacea. This is a medicine.
- Study limits
- A randomized trial of a marketed drug against another prescription drug. It supports ivermectin as a rosacea treatment. Funding came from the drug's developer (Ivermectin Phase III study group).
Where it comes from
- Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial
Published by British Journal of Dermatology (Taieb, Ortonne, Ruzicka, Roszkiewicz, Berth-Jones & Peirone) · Last checked 2026-10-26
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectMoisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial
In a randomized controlled trial of 75 patients with erythematotelangiectatic rosacea, a moisturizer containing Centella asiatica extract, ceramide NP and panthenol produced greater improvements in facial redness and barrier measures than the control group at day 28.
Human trial · 2026 · 75 people · patients with erythematotelangiectatic rosasma · Adults with erythematotelangiectatic rosacea using the combination moisturizer twice daily for 28 days, alongside oral minocycline. · Centella asiatica was one of three actives in the moisturizer; all adverse events were mild and self-limiting.
- Skin effectDoxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea
Low-dose (anti-inflammatory, sub-antimicrobial) oral doxycycline 40 mg once daily was significantly more effective than placebo at reducing inflammatory lesions in rosacea across two pivotal randomized, double-blind, placebo-controlled, multicenter trials (16 weeks). The 40 mg dose works as an anti-inflammatory.
Review article · 2010 · Adults with rosacea in two pivotal multicenter trials · Oral prescription treatment for inflammatory rosacea. A medicine. · The cited source is a published drug evaluation that summarizes two pivotal trials. Like the ivermectin evidence here. Low-dose doxycycline is anti-inflammatory and sub-antimicrobial, oral antibiotics carry their own considerations.
- Skin effectNiacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea
A facial moisturiser containing niacinamide improved stratum corneum barrier function and skin hydration, measured instrumentally, in people with rosacea over four weeks of twice-daily use.
Human trial · 2005 · 50 people · Adults with rosacea · A leave-on facial moisturiser, applied twice daily for four weeks, in adults with rosacea. · The tested article was a finished moisturiser. Fifty participants, one centre, four weeks. The study measured barrier function and hydration.